Sandostatin – A Second Line Hormone Therapy (Part 4 of a Series of Posts on Second Line Hormone Therapy)

Somastatin is a naturally occurring hormone that affects the levels of other hormone production in the body. Its most common drug use today is to treat giantism and acromegaley, a disease characterized by an over abundance of growth hormones. There is laboratory evidence that somastatin analogs such as octreotide acetate (Sandostatin/Sandoz) can affect the growth [...]

Leukine – A Second Line Hormone Therapy (Part 3 of a Series of Posts on Second Line Hormone Therapy)

Leukine, a granulocyte macrophage colony-stimulating factor (GM-CSF), is a hormone therapy that does not have an effect on a man’s testosterone production. Leukine is used by many physicians who are knowledgeable about the value of second line hormone therapy. Leukine works by stimulating the white blood cells (both increasing the overall production of the white [...]

Estrogen – A Second Line Hormone Therapy (Part 2 of a Series of Posts on Second Line Hormone Therapy)

One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]

Ketoconazole – A Second Line Hormone Therapy (Part 1 of a Series of Posts on Second Line Hormone Therapy)

At some point in the progression of advanced prostate cancer the usual initial standard of care, hormone therapy (ADT2 or ADT3), will fail to control the progression of the cancer. Commonly, when ADT does fail we will experience an increase in our PSA scores and often see signs of disease progression on imaging tests. For [...]

From the 2010 AUA Conference

For men with advanced prostate cancer adjuvant radiation therapy improves the cancer-specific survival of men with seminal vesicle invasion, even in the presence of nodal metastases. This underscores the need for multi-modal treatment approaches in advanced prostate cancer patients. Joel T. Nowak, M.A., M.S.W.

Go to Top